An acute treatment for migraines achieved both co-primary regulatory endpoints in 2 pivotal phase 3 trials.
Biohaven Pharmaceutical announced that its acute treatment for migraines achieved both co-primary regulatory endpoints in 2 pivotal phase 3 trials.
The pharmaceutical company’s rimegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist for the acute treatment of migraines, demonstrated superiority to placebo and met the co-primary endpoints of pain freedom and freedom from the most bothersome symptom at 2 hours in both BVH3000-301 and BVH3000-302. Researchers noted that these results were demonstrated with 1 dose and without rescue medications. According to the release, the overall efficacy and safety results were consistent across both trials.
“Clinicians have long awaited novel treatment modalities for migraine. The results from these 2 studies are very exciting as rimegepant met its regulatory endpoints and also showed important clinical benefit to patients,” said Richard B. Lipton, MD, vice chair of neurology, professor of epidemiology and population health and director of the Montefiore Headache Center at the Albert Einstein College of Medicine, and chair of Biohaven’s CGRP scientific advisory board, in a statement.
Click to continue reading on The American Journal of Managed Care.